Supplementary Materials

This PDF file includes:

  • Fig. S1. Cancer-related MEK mutants and their oncogenic potential.
  • Fig. S2. The MEK1 mutants with in-frame deletions of β3-αC loop are activated through homodimerization-driven transphosphorylation.
  • Fig. S3. MEK1 mutants with in-frame deletions of β3-αC loop exhibit differential inhibitor resistance in vitro and in vivo.
  • Fig. S4. The MEK inhibitors trametinib and AZD6244 block the AL phosphorylation of MEK1(ΔEI) and its activity.
  • Table S1. MEK1 mutations in cancer genomes.

[Download PDF]